Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 570

1.

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.

Elliott C, Belachew S, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Fecker J, Model F, Wei W, Arnold DL.

Brain. 2019 Sep 1;142(9):2787-2799. doi: 10.1093/brain/awz212.

2.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators.

Lancet Neurol. 2019 Sep 3. pii: S1474-4422(19)30238-8. doi: 10.1016/S1474-4422(19)30238-8. [Epub ahead of print]

PMID:
31492652
3.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.

Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators.

Lancet Neurol. 2019 Sep 3. pii: S1474-4422(19)30239-X. doi: 10.1016/S1474-4422(19)30239-X. [Epub ahead of print]

PMID:
31492651
4.

Hereditary defect of cobalamin metabolism with adolescence onset resembling multiple sclerosis: 41-year follow up in two cases.

Motte J, Kneiphof J, Straßburger-Krogias K, Pitarokoili K, Fisse AL, Kappos L, Gold R.

Ther Adv Neurol Disord. 2019 Aug 24;12:1756286419872115. doi: 10.1177/1756286419872115. eCollection 2019.

5.

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.

Barkhof F, Kappos L, Wolinsky JS, Li DKB, Bar-Or A, Hartung HP, Belachew S, Han J, Julian L, Sauter A, Napieralski J, Koendgen H, Hauser SL.

Neurology. 2019 Sep 4. pii: 10.1212/WNL.0000000000008189. doi: 10.1212/WNL.0000000000008189. [Epub ahead of print]

PMID:
31484710
6.

Video-based pairwise comparison: enabling the development of automated rating of motor dysfunction in multiple sclerosis.

Burggraaff J, Dorn J, D Souza M, Morrison C, Kamm CP, Kontschieder P, Tewarie P, Steinheimer S, Sellen A, Dahlke F, Kappos L, Uitdehaag B.

Arch Phys Med Rehabil. 2019 Aug 29. pii: S0003-9993(19)31047-0. doi: 10.1016/j.apmr.2019.07.016. [Epub ahead of print]

PMID:
31473205
7.

Hepatitis E virus infections in patients with MS on oral disease-modifying treatment.

Diebold M, Fischer-Barnicol B, Tsagkas C, Kuhle J, Kappos L, Derfuss T, Décard BF.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 11;6(5). pii: e594. doi: 10.1212/NXI.0000000000000594. Print 2019 Sep.

8.

Automatic Spinal Cord Gray Matter Quantification: A Novel Approach.

Tsagkas C, Horvath A, Altermatt A, Pezold S, Weigel M, Haas T, Amann M, Kappos L, Sprenger T, Bieri O, Cattin P, Parmar K.

AJNR Am J Neuroradiol. 2019 Sep;40(9):1592-1600. doi: 10.3174/ajnr.A6157. Epub 2019 Aug 22.

PMID:
31439628
9.

PML with dimethyl fumarate-No convincing case against natalizumab.

Diebold M, Altersberger V, Décard BF, Kappos L, Derfuss T, Lorscheider J.

Mult Scler. 2019 Aug 22:1352458519872894. doi: 10.1177/1352458519872894. [Epub ahead of print] No abstract available.

PMID:
31436113
10.

Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis.

Sinnecker T, Clarke MA, Meier D, Enzinger C, Calabrese M, De Stefano N, Pitiot A, Giorgio A, Schoonheim MM, Paul F, Pawlak MA, Schmidt R, Kappos L, Montalban X, Rovira À, Evangelou N, Wuerfel J; MAGNIMS Study Group.

JAMA Neurol. 2019 Aug 19. doi: 10.1001/jamaneurol.2019.2478. [Epub ahead of print]

PMID:
31424490
11.

Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years.

Cantó E, Barro C, Zhao C, Caillier SJ, Michalak Z, Bove R, Tomic D, Santaniello A, Häring DA, Hollenbach J, Henry RG, Cree BAC, Kappos L, Leppert D, Hauser SL, Benkert P, Oksenberg JR, Kuhle J.

JAMA Neurol. 2019 Aug 12. doi: 10.1001/jamaneurol.2019.2137. [Epub ahead of print]

PMID:
31403661
12.

Short timescale modulation of cortical and cerebellar activity in the early phase of motor sequence learning: an fMRI study.

Magon S, Pfister A, Laura G, Lüthi M, Papadopoulou A, Kappos L, Sprenger T.

Brain Imaging Behav. 2019 Jul 27. doi: 10.1007/s11682-019-00167-8. [Epub ahead of print]

PMID:
31352651
13.

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS.

Sormani MP, Haering DA, Kropshofer H, Leppert D, Kundu U, Barro C, Kappos L, Tomic D, Kuhle J.

Ann Clin Transl Neurol. 2019 May 28;6(6):1081-1089. doi: 10.1002/acn3.795. eCollection 2019 Jun.

14.

A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence.

Diebold M, Altersberger V, Décard BF, Kappos L, Derfuss T, Lorscheider J.

Mult Scler. 2019 Jun 18:1352458519852100. doi: 10.1177/1352458519852100. [Epub ahead of print]

PMID:
31208265
15.

Accurate, rapid and reliable, fully automated MRI brainstem segmentation for application in multiple sclerosis and neurodegenerative diseases.

Sander L, Pezold S, Andermatt S, Amann M, Meier D, Wendebourg MJ, Sinnecker T, Radue EW, Naegelin Y, Granziera C, Kappos L, Wuerfel J, Cattin P, Schlaeger R; Alzheimer's Disease Neuroimaging Initiative.

Hum Brain Mapp. 2019 Oct 1;40(14):4091-4104. doi: 10.1002/hbm.24687. Epub 2019 Jun 17.

PMID:
31206931
16.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1534. [Epub ahead of print]

PMID:
31206160
17.

Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide.

Sprenger T, Kappos L, Radue EW, Gaetano L, Mueller-Lenke N, Wuerfel J, Poole EM, Cavalier S.

Mult Scler. 2019 Jun 14:1352458519855722. doi: 10.1177/1352458519855722. [Epub ahead of print]

PMID:
31198103
18.

Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★.

Miller AE, Vermersch P, Kappos L, Comi G, Freedman MS, Oh J, de Seze J, Truffinet P, Benamor M, Purvis A, Wolinsky JS; TOPIC study group.

Mult Scler Relat Disord. 2019 Aug;33:131-138. doi: 10.1016/j.msard.2019.05.014. Epub 2019 May 24.

19.

Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials.

D'Souza M, Heikkilä A, Lorscheider J, Haller V, Kravalis K, Gysin S, Fuertes NAC, Fricker E, Lam E, Higgins P, Tomic D, Papadopoulou A, Kappos L.

Mult Scler. 2019 May 7:1352458519845108. doi: 10.1177/1352458519845108. [Epub ahead of print]

PMID:
31060429
20.

Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells.

Zimmermann M, Rose N, Lindner JM, Kim H, Gonçalves AR, Callegari I, Syedbasha M, Kaufmann L, Egli A, Lindberg RLP, Kappos L, Traggiai E, Sanderson NSR, Derfuss T.

Front Immunol. 2019 Apr 16;10:829. doi: 10.3389/fimmu.2019.00829. eCollection 2019.

21.

Damage of the lateral geniculate nucleus in MS: Assessing the missing node of the visual pathway.

Papadopoulou A, Gaetano L, Pfister A, Altermatt A, Tsagkas C, Morency F, Brandt AU, Hardmeier M, Chakravarty MM, Descoteaux M, Kappos L, Sprenger T, Magon S.

Neurology. 2019 May 7;92(19):e2240-e2249. doi: 10.1212/WNL.0000000000007450. Epub 2019 Apr 10.

PMID:
30971483
22.

Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.

Mehta D, Miller C, Arnold DL, Bame E, Bar-Or A, Gold R, Hanna J, Kappos L, Liu S, Matta A, Phillips JT, Robertson D, von Hehn CA, Campbell J, Spach K, Yang L, Fox RJ.

Neurology. 2019 Apr 9;92(15):e1724-e1738. doi: 10.1212/WNL.0000000000007262. Epub 2019 Mar 27.

23.

Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.

Mayer L, Kappos L, Racke MK, Rammohan K, Traboulsee A, Hauser SL, Julian L, Köndgen H, Li C, Napieralski J, Zheng H, Wolinsky JS.

Mult Scler Relat Disord. 2019 May;30:236-243. doi: 10.1016/j.msard.2019.01.044. Epub 2019 Jan 28.

PMID:
30844611
24.

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.

Turner B, Cree BAC, Kappos L, Montalban X, Papeix C, Wolinsky JS, Buffels R, Fiore D, Garren H, Han J, Hauser SL.

J Neurol. 2019 May;266(5):1182-1193. doi: 10.1007/s00415-019-09248-6. Epub 2019 Feb 28.

25.

Setwise comparison: efficient fine-grained rating of movement videos using algorithmic support - a proof of concept study.

Steinheimer S, Dorn JF, Morrison C, Sarkar A, D'Souza M, Boisvert J, Bedi R, Burggraaff J, Kontschieder P, Dahlke F, Sellen A, Uitdehaag BMJ, Kappos L, Kamm CP.

Disabil Rehabil. 2019 Feb 20:1-7. doi: 10.1080/09638288.2018.1563832. [Epub ahead of print]

PMID:
30782055
26.

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.

Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, Dahlke F, Tomic D, Leppert D, Kappos L.

Neurology. 2019 Mar 5;92(10):e1007-e1015. doi: 10.1212/WNL.0000000000007032. Epub 2019 Feb 8.

27.

Clinical associations of T2-weighted lesion load and lesion location in small vessel disease: Insights from a large prospective cohort study.

Altermatt A, Gaetano L, Magon S, Bauer L, Feurer R, Gnahn H, Hartmann J, Seifert CL, Poppert H, Wuerfel J, Radue EW, Kappos L, Sprenger T.

Neuroimage. 2019 Apr 1;189:727-733. doi: 10.1016/j.neuroimage.2019.01.052. Epub 2019 Jan 24.

PMID:
30685330
28.

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.

Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H.

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13.

PMID:
30636699
29.

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.

Naegelin Y, Naegelin P, von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ, Scotti B, Zecca C, Gobbi C, Kappos L, Derfuss T.

JAMA Neurol. 2019 Mar 1;76(3):274-281. doi: 10.1001/jamaneurol.2018.4239.

PMID:
30615019
30.

Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis.

Ruberte E, Sinnecker T, Amann M, Gaetano L, Naegelin Y, Penner IK, Kuhle J, Derfuss T, Kappos L, Granziera C, Wuerfel J, Yaldizli Ö.

Eur Neurol. 2018;80(3-4):207-214. doi: 10.1159/000495798. Epub 2019 Jan 3.

PMID:
30605898
31.

Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.

Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, Kappos L, Pozzilli C, Montalban X, De Stefano N; and the MAGNIMS Study Group.

Neurology. 2019 Jan 22;92(4):180-192. doi: 10.1212/WNL.0000000000006810. Epub 2018 Dec 26. Review.

32.

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.

Elliott C, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Wei W, Belachew S, Arnold DL.

Mult Scler. 2018 Dec 19:1352458518814117. doi: 10.1177/1352458518814117. [Epub ahead of print]

PMID:
30566027
33.

Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.

Chitnis T, Gonzalez C, Healy BC, Saxena S, Rosso M, Barro C, Michalak Z, Paul A, Kivisakk P, Diaz-Cruz C, Sattarnezhad N, Pierre IV, Glanz BI, Tomic D, Kropshofer H, Häring D, Leppert D, Kappos L, Bakshi R, Weiner HL, Kuhle J.

Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491. doi: 10.1002/acn3.638. eCollection 2018 Dec.

34.

Learning ability correlates with brain atrophy and disability progression in RRMS.

Sormani MP, De Stefano N, Giovannoni G, Langdon D, Piani-Meier D, Haering DA, Kappos L, Tomic D.

J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):38-43. doi: 10.1136/jnnp-2018-319129. Epub 2018 Oct 15.

35.

Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.

Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group.

Eur J Neurol. 2019 Feb;26(2):363-370. doi: 10.1111/ene.13824. Epub 2018 Nov 2.

PMID:
30298572
36.

Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus.

Pröbstel AK, Thanei M, Erni B, Lecourt AC, Branco L, André R, Roux-Lombard P, Koenig KF, Huynh-Do U, Ribi C, Chizzolini C, Kappos L, Trendelenburg M, Derfuss T; Swiss Systemic Lupus Erythematosus Cohort Study Group.

Rheumatology (Oxford). 2019 May 1;58(5):908-913. doi: 10.1093/rheumatology/key282.

PMID:
30265368
37.

Design and construction of an innovative brain phantom prototype for MRI.

Altermatt A, Santini F, Deligianni X, Magon S, Sprenger T, Kappos L, Cattin P, Wuerfel J, Gaetano L.

Magn Reson Med. 2019 Feb;81(2):1165-1171. doi: 10.1002/mrm.27464. Epub 2018 Sep 17.

PMID:
30221790
38.

A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression.

Nakamura Y, Gaetano L, Matsushita T, Anna A, Sprenger T, Radue EW, Wuerfel J, Bauer L, Amann M, Shinoda K, Isobe N, Yamasaki R, Saida T, Kappos L, Kira JI.

J Neuroinflammation. 2018 Sep 5;15(1):255. doi: 10.1186/s12974-018-1295-1.

39.

Neurofilaments as biomarkers in neurological disorders.

Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J.

Nat Rev Neurol. 2018 Oct;14(10):577-589. doi: 10.1038/s41582-018-0058-z. Review.

PMID:
30171200
40.

Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis.

van Munster CE, D'Souza M, Steinheimer S, Kamm CP, Burggraaff J, Diederich M, Kravalis K, Dorn J, Walsh L, Dahlke F, Kappos L, Uitdehaag BM.

Mult Scler. 2018 Aug 31:1352458518796690. doi: 10.1177/1352458518796690. [Epub ahead of print]

41.

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.

Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, Chin P, Belachew S, Kappos L.

Ann Neurol. 2018 Oct;84(4):527-536. doi: 10.1002/ana.25313.

42.

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, Sprenger T, Radue EW, Wuerfel J, Nichols TE.

Brain Imaging Behav. 2019 Oct;13(5):1361-1374. doi: 10.1007/s11682-018-9942-9.

PMID:
30155789
43.

Reference videos reduce variability of motor dysfunction assessments in multiple sclerosis.

D'Souza M, Steinheimer S, Dorn J, Morrison C, Boisvert J, Kravalis K, Burggraaff J, van Munster CE, Diederich M, Sellen A, Kamm CP, Dahlke F, Uitdehaag BM, Kappos L.

Mult Scler J Exp Transl Clin. 2018 Aug 9;4(3):2055217318792399. doi: 10.1177/2055217318792399. eCollection 2018 Jul-Sep.

44.

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.

Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, Lugaresi A, Grammond P, Sola P, Ferraro D, Grand'Maison F, Alroughani R, Terzi M, Boz C, Hupperts R, Lechner-Scott J, Kappos L, Pucci E, Hodgkinson S, Solaro C, Butzkueven H.

J Neurol Sci. 2018 Aug 15;391:72-76. doi: 10.1016/j.jns.2018.06.001. Epub 2018 Jun 2.

PMID:
30103975
45.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators.

Mult Scler. 2019 Aug;25(9):1255-1262. doi: 10.1177/1352458518789884. Epub 2018 Jul 25.

46.

Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.

Naegelin Y, Rasenack M, Andelova M, Von Felten S, Fischer-Barnicol B, Amann M, Mehling M, Kappos L, Sprenger T, Derfuss T.

Mult Scler Relat Disord. 2018 Oct;25:14-20. doi: 10.1016/j.msard.2018.07.005. Epub 2018 Jul 6.

47.

Spinal cord volume loss: A marker of disease progression in multiple sclerosis.

Tsagkas C, Magon S, Gaetano L, Pezold S, Naegelin Y, Amann M, Stippich C, Cattin P, Wuerfel J, Bieri O, Sprenger T, Kappos L, Parmar K.

Neurology. 2018 Jul 24;91(4):e349-e358. doi: 10.1212/WNL.0000000000005853. Epub 2018 Jun 27.

PMID:
29950437
48.

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.

Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, Leppert D, Gobbi C, Granziera C, Yaldizli Ö, Michalak Z, Wuerfel J, Kappos L, Parmar K, Kuhle J.

Brain. 2018 Aug 1;141(8):2382-2391. doi: 10.1093/brain/awy154.

PMID:
29860296
49.

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; Tysabri® Observational Program (TOP) Investigators.

Mult Scler Relat Disord. 2018 Aug;24:11-19. doi: 10.1016/j.msard.2018.04.020. Epub 2018 May 2.

50.

Clinical Correlations of Brain Lesion Location in Multiple Sclerosis: Voxel-Based Analysis of a Large Clinical Trial Dataset.

Altermatt A, Gaetano L, Magon S, Häring DA, Tomic D, Wuerfel J, Radue EW, Kappos L, Sprenger T.

Brain Topogr. 2018 Sep;31(5):886-894. doi: 10.1007/s10548-018-0652-9. Epub 2018 May 29.

PMID:
29845492

Supplemental Content

Loading ...
Support Center